GenScript ProBio and RVAC Medicines Pte. Ltd. announced an agreement to establish a strategic partnership for the manufacturing of GMP-grade plasmid DNA (pDNA) for its mRNA COVID-19 vaccine candidate, RVM-V001, along with collaboration for future therapeutic pipelines.
GenScript ProBio will provide GMP plasmid manufacturing service for RVAC Medicines’ program, RVM-V001. This partnership will enable to accelerate its clinical manufacturing of mRNA-based COVID-19 vaccine, RVM-V001, and future mRNA-based vaccines targeting infectious diseases such as Respiratory syncytial virus (RSV) and Clostriodioides difficile infection (CDI).
Dr. Brian Min, CEO of GenScript ProBio said, “We are delighted to enter into this strategic partnership with RVAC Medicines. This collaboration will enable us to utilize our cutting-edge GMP plasmid manufacturing platform technology to support the development of mRNA-based COVID-19 vaccine and its therapeutic candidates.”
Dr. Sean Fu, CEO of RVAC Medicines said, “We are excited to work closely with GenScript ProBio. With its technical strength and customer centric approach, GenScript ProBio will help to accelerate the development of RVAC’s pipeline.”
As RVAC advances the development of its mRNA candidates, GenScript ProBio continues to provide high-quality GMP materials critical to the mission, including plasmid DNA and the development of ancillary materials to support mRNA manufacturing process. In addition to the manufacturing of plasmid DNA, the GenScript ProBio team provides consultative and expert guidance regarding quality and regulatory expectations of agencies worldwide.
RVAC Medicines will continue to collaborate with GenScript ProBio to support its mRNA initiatives for both clinical-stage development and commercial stage.